StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
152
This month
4
This week
1
This year
12
Yesterday
1
Publishing Date
2023 - 10 - 23
3
2023 - 10 - 12
2
2023 - 09 - 11
3
2023 - 07 - 27
2
2023 - 06 - 28
2
2023 - 06 - 05
3
2023 - 05 - 30
2
2023 - 02 - 02
2
2022 - 12 - 07
2
2022 - 12 - 06
2
2022 - 11 - 08
2
2022 - 08 - 15
2
2022 - 08 - 12
2
2022 - 08 - 01
2
2022 - 07 - 25
2
2022 - 06 - 03
2
2022 - 05 - 16
2
2022 - 05 - 12
2
2022 - 05 - 05
2
2022 - 03 - 21
2
2022 - 03 - 03
2
2022 - 03 - 02
1
2022 - 02 - 22
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2022 - 01 - 03
1
2021 - 12 - 23
1
2021 - 12 - 15
1
2021 - 12 - 14
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 19
1
2021 - 11 - 18
1
2021 - 11 - 04
1
2021 - 11 - 02
1
2021 - 10 - 25
1
2021 - 10 - 19
1
2021 - 10 - 06
1
2021 - 10 - 04
1
2021 - 09 - 17
1
2021 - 08 - 12
1
2021 - 08 - 05
2
2021 - 08 - 02
1
2021 - 07 - 19
1
2021 - 07 - 08
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 07
1
2021 - 06 - 02
1
2021 - 05 - 20
1
2021 - 05 - 12
2
2021 - 05 - 10
1
2021 - 05 - 06
1
2021 - 05 - 05
1
2021 - 04 - 30
1
2021 - 04 - 27
1
2021 - 04 - 20
1
2021 - 01 - 12
1
2021 - 01 - 11
1
2020 - 12 - 23
1
Sector
Commercial services
1
Consumer services
1
Health services
2
Health technology
152
Manufacturing
4
N/a
1
Tags
Acquire
4
Agreement
4
Alliances
24
Antibody
6
Application
3
Approval
5
Approved
6
Asia
5
Astrazeneca
5
Biocapital
6
Biotech
11
Biotech-bay
3
Biotech-beach
5
Breast
7
Breast cancer
11
Cancer
60
Cel
3
Cell
8
Clinical-trials-phase-ii
7
Clinical-trials-phase-iii
16
Collaboration
9
Conference
4
Drug
7
Earnings
7
Enhertu
24
Europe
6
Events
7
Fda
6
Genetown
6
Granted
6
Her2
26
Her2-
17
Initiated
7
License
12
Lung
18
Lung cancer
4
Mergers-and-acquisitions
5
Metastatic breast cancer
11
Negative
5
Partnership
6
People
10
Pharma
4
Pharmaceutical
6
Phase 2
4
Phase 3
6
Positive
11
Program
4
Regulatory
8
Research
19
Results
11
Review
8
Risk
4
Study
4
Test
4
Therapeutics
6
Therapy
11
Treatment
10
Trial
30
Tumor
4
Tumors
6
Entities
Abbott laboratories
226
Abbvie inc.
241
Agilent technologies, inc.
114
Alnylam pharmaceuticals, inc.
162
Alphabet inc.
224
Amarin corporation plc
179
Amgen inc.
173
Arrival
119
Arrowhead pharmaceuticals, inc.
95
Astrazeneca plc
152
Bausch health companies inc.
110
Becton, dickinson and company
106
Beigene, ltd.
193
Bio-techne corp
103
Biogen inc.
118
Bristol-myers squibb company
338
Bruker corporation
107
Castle biosciences, inc.
152
Charles river laboratories international, inc.
97
Cybin inc
129
Eli lilly and company
590
Evotec se
110
Gilead sciences, inc.
275
Horizon therapeutics public limited company
139
I-mab
117
Incyte corporation
166
Johnson & johnson
1711
Laboratory corporation of america holdings
100
Lineage cell therapeutics, inc.
101
Medtronic plc
138
Merck & company, inc.
316
Mirum pharmaceuticals, inc.
114
Moderna, inc.
292
Morgan stanley
429
Morphosys ag
290
Nanostring technologies, inc.
108
Natera, inc.
97
Nektar therapeutics
293
Novartis ag
126
Novavax, inc.
96
Novo nordisk a/s
113
Oncocyte corporation
201
Orange
338
Perrigo company
121
Pfizer, inc.
261
Ptc therapeutics, inc.
203
Rallybio corp
97
Regeneron pharmaceuticals, inc.
111
Relief therapeutics holding sa
98
Sanofi
1733
Seres therapeutics, inc.
102
Takeda pharmaceutical company limited
236
Teva pharmaceutical industries ltd
117
Therapeuticsmd, inc.
233
Thermo fisher scientific inc
215
Twist bioscience corporation
161
Vaxart, inc.
227
Veracyte, inc.
108
Vertex pharmaceuticals incorporated
112
Xencor, inc.
101
Symbols
ABBV
1
ABT
1
ADVM
1
ALPMF
1
ALPMY
1
AMGN
3
ANPCF
1
ANPCY
1
ARDS
1
ARTL
7
ATXI
3
AVTX
1
AZN
152
AZNCF
51
BGNE
1
BIIB
1
BMY
2
BNTX
1
BPMC
2
CGEN
3
CKPT
1
CRL
1
DERM
2
EBAY
1
FBIO
15
FSTX
2
FUSN
3
GILD
1
GLAXF
2
GLPG
1
GLPGF
1
GMAB
1
GNMSF
1
GNPX
7
GRCL
1
GSK
3
HLN
1
HLNCF
1
ICVX
1
ILMN
4
IPHA
3
IPHYF
3
JNJ
4
LGND
1
LLY
4
MBIO
2
MEDE
1
MOR
1
MRNA
1
NBIX
1
NEO
1
NKTR
1
NRBO
1
NVO
5
NVS
1
NVTA
1
PFE
2
PODD
1
SNY
6
SNYNF
5
Exchanges
Amex
1
Nasdaq
152
Nyse
17
Crawled Date
2023 - 10 - 23
3
2023 - 10 - 12
2
2023 - 09 - 11
3
2023 - 07 - 27
2
2023 - 06 - 28
2
2023 - 06 - 05
3
2023 - 05 - 30
2
2023 - 02 - 02
2
2022 - 12 - 07
2
2022 - 12 - 06
2
2022 - 11 - 08
2
2022 - 08 - 15
2
2022 - 08 - 12
2
2022 - 08 - 01
2
2022 - 07 - 25
2
2022 - 06 - 03
2
2022 - 05 - 16
2
2022 - 05 - 12
2
2022 - 05 - 05
2
2022 - 03 - 21
2
2022 - 03 - 03
2
2022 - 03 - 02
1
2022 - 02 - 22
1
2022 - 02 - 21
1
2022 - 01 - 17
1
2022 - 01 - 03
1
2021 - 12 - 23
1
2021 - 12 - 15
1
2021 - 12 - 14
1
2021 - 12 - 09
1
2021 - 11 - 30
1
2021 - 11 - 19
1
2021 - 11 - 18
1
2021 - 11 - 05
1
2021 - 11 - 02
1
2021 - 10 - 25
1
2021 - 10 - 19
1
2021 - 10 - 06
1
2021 - 10 - 04
1
2021 - 09 - 17
1
2021 - 08 - 12
1
2021 - 08 - 05
2
2021 - 08 - 02
1
2021 - 07 - 19
1
2021 - 07 - 08
1
2021 - 06 - 11
1
2021 - 06 - 08
1
2021 - 06 - 07
1
2021 - 06 - 02
1
2021 - 05 - 20
1
2021 - 05 - 12
2
2021 - 05 - 10
1
2021 - 05 - 06
1
2021 - 05 - 05
1
2021 - 04 - 30
1
2021 - 04 - 27
1
2021 - 04 - 20
1
2021 - 01 - 12
1
2021 - 01 - 11
1
2020 - 12 - 23
1
Crawled Time
00:00
2
02:00
1
06:00
2
07:00
1
08:00
7
09:00
8
10:00
7
11:00
10
12:00
16
12:20
2
13:00
13
13:15
1
13:20
3
13:30
2
14:00
15
14:15
1
14:20
3
14:30
2
15:00
6
15:20
2
15:30
4
16:00
6
17:00
11
18:00
5
19:00
9
20:00
2
21:00
5
22:00
4
23:00
2
Source
investor.aveooncology.com
2
ir.chemocentryx.com
1
www.biospace.com
152
www.chi-med.com
2
www.globenewswire.com
70
www.prnewswire.com
440
www.sutrobio.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Astrazeneca plc
source :
Www.biospace.com
save search
Angle PLC Announces New Commercial Agreement with AstraZeneca
Published:
2024-04-24
(Crawled : 09:00)
- biospace.com/
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
-3.53%
|
O:
-3.53%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
1.12%
|
O:
1.42%
H:
0.08%
C:
-0.29%
astrazeneca
commercial
agreement
Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials
Published:
2024-04-16
(Crawled : 14:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
3.59%
|
O:
-0.64%
H:
0.45%
C:
-0.04%
million
series
trials
program
FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published:
2024-04-11
(Crawled : 12:00)
- biospace.com/
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
-0.66%
|
O:
1.47%
H:
1.16%
C:
-1.27%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
5.29%
|
O:
3.34%
H:
0.27%
C:
-0.62%
children
approved
treatment
for
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer
Published:
2024-04-02
(Crawled : 08:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
4.78%
|
O:
-1.18%
H:
0.34%
C:
-0.22%
breast
her2
license
cancer
application
negative
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateMajor achievements in 2023 lay the foundation for key upcoming milestones
Published:
2024-03-25
(Crawled : 16:00)
- biospace.com/
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
2.25%
|
O:
0.75%
H:
0.04%
C:
-0.1%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
7.46%
|
O:
-0.08%
H:
0.33%
C:
-0.53%
ARTL
|
News
|
$1.3418
2.43%
0.0%
2
|
Health Technology
|
-11.84%
|
O:
-4.61%
H:
4.83%
C:
3.84%
business
lay
key
financial
results
foundation
AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Published:
2024-03-19
(Crawled : 12:00)
- biospace.com/
FUSN
|
$21.4
-0.09%
-0.09%
320
|
Health Technology
|
101.13%
|
O:
96.99%
H:
1.19%
C:
1.05%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
8.12%
|
O:
-0.38%
H:
0.46%
C:
0.4%
astrazeneca
cancer
treat
acquire
GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study
Published:
2024-03-18
(Crawled : 13:30)
- biospace.com/
ILMN
|
$122.87
-1.28%
-1.4%
330
|
Health Technology
|
-3.8%
|
O:
0.51%
H:
2.49%
C:
1.37%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
7.37%
|
O:
-0.45%
H:
0.55%
C:
-0.24%
lung
test
cancer
risk
study
PharmaDrug Appoints Current Board Member Dr. David Kideckel as Chairman
Published:
2024-02-27
(Crawled : 15:30)
- biospace.com/
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
4.12%
|
O:
-1.72%
H:
2.54%
C:
2.54%
JNJ
|
News
|
$148.53
-0.69%
0.11%
67K
|
Health Technology
|
-8.41%
|
O:
-1.07%
H:
0.0%
C:
0.0%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
7.99%
|
O:
0.01%
H:
0.79%
C:
0.6%
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
Published:
2024-02-23
(Crawled : 21:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
11.02%
|
O:
1.29%
H:
1.49%
C:
1.34%
show
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Published:
2024-02-19
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
Email alert
Add to watchlist
lung
license
cancer
cell
application
advanced
BioInvent to Evaluate BI-1206 in Combination with Rituximab and Calquence
Published:
2024-02-09
(Crawled : 09:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
12.09%
|
O:
-1.28%
H:
1.05%
C:
-0.72%
bi-1206
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published:
2024-01-29
(Crawled : 11:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
6.11%
|
O:
0.24%
H:
0.07%
C:
-0.1%
enhertu
her2
granted
review
tumors
positive
AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
Published:
2023-12-26
(Crawled : 10:00)
- biospace.com/
GRCL
|
$10.25
-0.29%
6.4M
|
Manufacturing
|
59.92%
|
O:
54.84%
H:
0.0%
C:
0.0%
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
3.4%
|
O:
3.01%
H:
0.0%
C:
-0.33%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
7.41%
|
O:
0.32%
H:
0.21%
C:
0.0%
astrazeneca
cell
acquire
therapy
Two Phase 3 Trials of Datopotamab Deruxtecan Plus Durvalumab Initiated in Patients Across Two Breast Cancer Subtypes
Published:
2023-12-18
(Crawled : 00:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
9.88%
|
O:
1.03%
H:
1.08%
C:
0.73%
breast
cancer
trials
plus
initiated
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published:
2023-12-12
(Crawled : 15:30)
- biospace.com/
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
8.11%
|
O:
5.03%
H:
0.0%
C:
-3.82%
ICVX
|
$15.31
-0.65%
9.3M
|
|
50.64%
|
O:
53.48%
H:
1.02%
C:
0.26%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
12.13%
|
O:
1.54%
H:
0.06%
C:
-0.78%
vaccine
astrazeneca
positive
acquire
rsv
potential
Long-term ALPHA Phase III trial data showed danicopan as add-on to ULTOMIRIS® or SOLIRIS® sustained clinical improvements in subset of patients with PNH experiencing clinically significant extravascular hemolysis
Published:
2023-12-11
(Crawled : 08:00)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
12.57%
|
O:
0.46%
H:
0.22%
C:
-0.06%
ultomiris
trial
Validation Data on a Novel Prognostic Test Developed by GRAIL in Stage I Lung Cancer Presented at North America Conference on Lung Cancer
Published:
2023-12-06
(Crawled : 22:00)
- biospace.com/
ILMN
|
$122.87
-1.28%
-1.4%
330
|
Health Technology
|
9.94%
|
O:
1.4%
H:
3.94%
C:
0.58%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
11.23%
|
O:
0.73%
H:
0.06%
C:
-1.38%
america
lung
conference
test
cancer
Presage Biosciences Announces New Pharma Partnership to Evaluate Novel Immuno-Oncology Drug Combinations with CIVO® Technology
Published:
2023-11-30
(Crawled : 15:30)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
11.04%
|
O:
-0.23%
H:
1.45%
C:
0.97%
civo
partnership
pharma
drug
technology
AstraZeneca advances scientific leadership in hematology at ASH 2023
Published:
2023-11-29
(Crawled : 15:30)
- biospace.com/
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
12.48%
|
O:
1.33%
H:
0.3%
C:
-0.03%
astrazeneca
Pfizer Reports Third-Quarter 2023 Results
Published:
2023-10-31
(Crawled : 12:00)
- biospace.com/
HLNCF
|
$4.02
-2.66%
-1.48%
0
|
n/a
|
4.82%
|
O:
2.0%
H:
0.5%
C:
0.5%
HLN
|
$8.35
-0.71%
0.0%
6
|
n/a
|
4.11%
|
O:
0.75%
H:
0.74%
C:
0.12%
AZNCF
|
News
|
$135.35
-3.53%
-4.19%
0
|
Health Technology
|
9.18%
|
O:
0.73%
H:
0.0%
C:
-1.7%
PFE
|
News
4
|
$26.27
-0.19%
-0.38%
130K
|
Health Technology
|
-14.01%
|
O:
-0.87%
H:
1.77%
C:
0.91%
BNTX
|
News
|
$88.09
-0.45%
-0.35%
1.9K
|
Health Technology
|
-5.53%
|
O:
-1.65%
H:
2.78%
C:
2.0%
AZN
|
News
|
$71.2
0.49%
0.46%
300K
|
Health Technology
|
13.12%
|
O:
0.08%
H:
0.41%
C:
0.38%
results
← Previous
1
2
3
4
5
6
7
8
Next →
Gainers vs Losers
60%
40%
Top 10 Gainers
BOF
|
$2.08
77.78%
39.06%
110M
|
OPTN
|
$0.9253
-4.38%
30.38%
5.3M
|
Health Services
PCSA
|
$1.62
1.25%
21.95%
7.1M
|
Producer Manufacturing
BHIL
|
$0.1793
-4.37%
19.24%
340K
|
Agriculture, Forestry, Fishing ...
UMAC
|
$1.48
-1.33%
14.87%
20K
|
CI
|
$352.28
-0.11%
13.53%
2
|
Health Services
CIG.C
|
$2.89
-1.37%
12.8%
2.3K
|
n/a
BMTX
4
|
$1.545
0.98%
10.03%
2.5K
|
Information
OMQS
|
$0.411
-2.81%
9.83%
1.2M
|
Professional, Scientific, and T...
TAL
|
$12.26
0.57%
9.22%
12M
|
Consumer Services
Your saved searches
Save your searches and get alerts when important news are released.